Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum 
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
The EU is implementing policies to give patients easier access to cheaper, generic medicines, which could cut the revenues of big pharmaceutical firms.
According to an EU document yet to be published, the European Commission (EC) will consider targeted policies that support a greater generic and biosimilar competition to make drugs more affordable and preventing dramatic shortages.
The EU will apply its antitrust rules more strictly to stop patent-holding pharmaceutical firms from hindering the entry or expansion of generic and biosimilar competitors who offer more affordable medicines.
Among the EU’s possible actions, expected in 2022, is the implementation of clearer provisions for the conduct of trials on patented products to support generic marketing authorization applications.
The EU will also renew incentives and obligations for pharma firms to allow wider distribution and greater competition.
This could require drugmakers to make their patented drugs available in all 27 states in the EU, including smaller countries that big drugmakers find less profitable, or risk shortening the period of their intellectual property rights.
Among medicines that are in short supply or unavailable in the EU are antibiotics and drugs for children and rare diseases.
Shortages in the bloc worsened during the first phase of the pandemic amid export bans and other trade restrictions and when India curbed the export of paracetamol.
